[Retracted] A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy

Table 2

Summary of PD-1/PD-L1 antibodies in several clinical evaluations.

PD-1/PD-L1 antibody applied in NPC patients	Clinical trial phase	Objective response rate	The 1-year OS rate	The 1-year DFS rate	References
Nivolumab	II	20.5%.	59%	19.3%	[41]
Pembrolizumab	I	25.9%	63%	33.4%	[42]
Camrelizumab	I	34%	—	27.1%	[43]